Tscan Therapeutics, Inc. - TCRX STOCK NEWS

TScan Therapeutics (Nasdaq: TCRX), a clinical-stage biotech company specializing in TCR-engineered T cell therapies for cancer treatment, has announced its participation in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. The company will engage in a fireside chat scheduled for Tuesday, February 25, 2025, at 10:00 a.m. Eastern Time.

Interested parties can access the webcast through the 'Events and Presentations' section on TScan's investor relations website at ir.tscan.com. The presentation recording will remain available for replay on the company's website for 90 days after the event.

TScan Therapeutics (NASDAQ: TCRX) has secured a $30 million registered direct offering through the sale of pre-funded warrants to Lynx1 Capital Management LP and its advised fund. The warrants, priced at $4.00 each, will allow the purchase of up to 7,500,000 shares of voting common stock at $0.0001 per share, representing a 37% premium to the last closing price and a 34% premium over the 10-day volume weighted average closing price.

The financing, expected to close around December 27, 2024, extends TScan's operational runway from Q4 2026 to Q1 2027. The transaction builds upon Lynx1's existing investment in TScan, demonstrating continued support for the company's development of TCR-T cell therapies for cancer treatment.

TScan Therapeutics (NASDAQ: TCRX) has secured a term loan facility of up to $52.5 million from Silicon Valley Bank (SVB). The first tranche of $32.5 million will retire existing convertible debt with K2 Health Ventures, with the remaining funds for general corporate purposes. A second $20.0 million tranche can be drawn through June 2026.

The loan bears interest at the greater of 7.00% or prime rate minus 0.75%, capped at 9.75%. Maturity is set for September 2029, with interest-only payments until September 2027, subject to meeting certain milestones. The company expects its cash resources to fund operations into Q4 2026.

TScan Therapeutics (NASDAQ: TCRX) presented updated results from their ALLOHA™ Phase 1 trial of TSC-100 and TSC-101, treatments designed to prevent relapse in patients with AML, ALL, and MDS post-transplant. The trial enrolled 38 patients (26 treatment, 12 control).

Key findings show significantly better event-free survival in the treatment arm (HR=0.30; p=0.04) with lower relapse rates (8% vs 33% in control). No dose-limiting toxicities were observed, and treatments were well-tolerated across all dose levels. Notably, among patients with TP53 mutations, none of the 4 treated patients relapsed, while both control patients relapsed within 6 months.

Based on these results, the company plans to launch a pivotal trial in the second half of 2025.

TScan Therapeutics (Nasdaq: TCRX) has been recognized as one of the Top Places to Work in Massachusetts by The Boston Globe for the third consecutive year. The recognition is based on an employee survey conducted by Energage, involving nearly 68,000 employees across 323 Massachusetts organizations. The survey evaluates various aspects including company direction, execution, management, work environment, compensation, and employee engagement.

The company, which focuses on developing TCR-engineered T cell therapies for cancer treatment, was evaluated among different workplace categories based on employee count. CEO Gavin MacBeath highlighted the company's commitment to advancing their clinical-stage pipeline for heme malignancies and solid tumors, while SVP of Human Resources Ann Hargraves emphasized the organization's growth and culture development over the past five years.

TScan Therapeutics (Nasdaq: TCRX) announces a virtual KOL event to discuss data from their ALLOHA™ Phase 1 heme trial presented at the ASH Annual Meeting and their clinical development strategy. The event, scheduled for December 10 at 8:00 a.m. ET, will review preliminary results of TSC-100 and TSC-101 in patients with AML, ALL, and MDS undergoing allogeneic hematopoietic cell transplantation. The company will also provide updates on their PLEXI-T™ Phase 1 solid tumor trial and discuss potential registrational pathways following their FDA meeting.

TScan Therapeutics (NASDAQ: TCRX) reported Q3 2024 financial results with revenue of $1.0 million, down from $3.9 million in Q3 2023. Net loss widened to $29.9 million from $23.0 million year-over-year. R&D expenses increased to $26.3 million, while G&A expenses rose to $7.4 million.

The company's ALLOHA Phase 1 trial showed promising results with no relapses in 16 treatment-arm patients, including five patients at one-year post-transplant. Cash position stands at $271.1 million, expected to fund operations into Q4 2026. TScan plans to present updated trial data at the upcoming ASH Annual Meeting and remains on track to dose its first patient with multiplex TCR-T therapy.

TScan Therapeutics (NASDAQ: TCRX) announced preliminary results from the ALLOHA™ Phase 1 trial of TSC-100 and TSC-101 for blood cancers. The trial enrolled 27 patients, with 16 in the treatment arm and 11 in the control arm. Key findings showed no relapses in the treatment arm versus three relapses in the control arm, with a median time to relapse of 159 days in the control group. All five TSC-treated patients reaching one-year follow-up remained relapse-free and MRD negative. No dose-limiting toxicities were reported, and safety profiles were similar between treatment and control arms.

TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houston, TX and virtually.

The presentations include:

• Discovery of a MAGE-A4-specific TCR-T Therapy Candidate for Multiplex Treatment of Solid Tumors
• Preclinical Models for T-Plex, a Customized Multiplexed TCR-T Cell Therapy Addressing Intra-Tumor Antigen and HLA Heterogeneity
• Development of a Target Agnostic Platform to Assess the Reactivity of TCR-T Therapies to Primary Human Tissues

All presentations will take place in the Exhibit Halls AB at the George R. Brown Convention Center. The presentation materials will be available on TScan's website after the event concludes.